Skip to Main Content

Cassava Sciences (SAVA) CEO Remi Barbier is 13 days away from a $3 million cash bonus, thanks to a well-timed change in the company’s executive compensation plan and a questionable reanalysis of an unsuccessful Alzheimer’s disease drug clinical trial.

Barbier has a reputation for profiting personally even while his company suffered multiple setbacks. This latest money grab is particularly shameless because it’s practically risk-free — for him.


And the $3 million that Barbier is on track to receive on Oct. 15 — as long as Cassava’s market cap stays above $200 million for 20 consecutive days — is just the start. He could make millions of dollars more in future bonus payments by pumping Cassava’s market value higher, justified or not.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.